Paion AG (PA8.F) stock: key figures, P/E, revenue and dividend

Energy · Coal & Consumable Fuels · Germany · ISIN DE000A0B65S3

Price
0.05 EUR
Market cap
328,150.15 EUR
P/E (2022)
–
P/S (2022)
0.01
Dividend yield
0.00 %
Net margin
-1.74 %
Return on equity (ROE)
-8.75 %
Return on assets (ROA)
-1.52 %

Paion AG financials

Fiscal year20212022
Revenue7.13 m EUR33.25 m EUR
Gross profit4.05 m EUR31.29 m EUR
Operating income-22.01 m EUR1.51 m EUR
EBIT-22.19 m EUR569,000.00 EUR
Net income-21.79 m EUR-579,000.00 EUR
Diluted EPS – continuing operations-0.31 EUR-0.08 EUR

Full history since 2013, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Paion AG

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and intensive care medicine services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.